The European Union (EU) will use Bavarian Nordic’s smallpox vaccine to combat the region’s current monkeypox outbreak. The European Health Emergency Preparedness and Response Authority (HERA) and the Danish producer Bavarian Nordic have agreed to purchase 110,000 doses of the vaccine. In Europe, the vaccine is known as IMVANEX, in the United States as JYNNEOS, and in Canada as IMVAMUNE.
In response to the current monkeypox outbreak, the vaccine will be made available to EU Member States, Norway, and Iceland, according to a statement released by Bavarian Nordic. It added that vaccine supply to HERA will begin immediately and be finished within the next few months.
According to Paul Chaplin, President and CEO of Bavarian Nordic: “We are glad to have reached an agreement with HERA to supply our vaccine, which will help to boost EU readiness and reaction during the current monkeypox outbreak in Europe. While we have already given considerable quantities of our vaccine to some individual EU member states, the supply to HERA now permits a more integrated and coordinated approach across the entire EU, in keeping with HERA’s objective.”
